In the BioHarmony Drug Report Database

"Preview" Icon

Tasimelteon

Hetlioz (tasimelteon) is a small molecule pharmaceutical. Tasimelteon was first approved as Hetlioz on 2014-01-31. It is used to treat circadian rhythm sleep disorders in the USA. It has been approved in Europe to treat circadian rhythm sleep disorders. The pharmaceutical is active against melatonin receptor type 1A and melatonin receptor type 1B. Hetlioz’s patents are valid until 2035-08-29 (FDA).

 

Trade Name

 

Hetlioz
 

Common Name

 

tasimelteon
 

ChEMBL ID

 

CHEMBL2103822
 

Indication

 

circadian rhythm sleep disorders
 

Drug Class

 

Selective melatonin receptor agonist

Image (chem structure or protein)

Tasimelteon structure rendering